SURMOUNT ‐ REAL UK : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity
Study context
- Population
- Adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m²) without diabetes, UK primary care, Greater Manchesterplanned enrolment (approximately)
- Participants
- 3,000 adults
- Planned comparison
- Tirzepatide + standard-of-care (SoC) vs SoC alone
- Primary endpoint
- Percent change in body weight from baseline
- Follow-up
- Month 24
Methodological detailsstudy design/protocol, 5-year, phase 4, multicenter, open-label, pragmatic, 1:1 randomization, integrated electronic healthcare record data, Key secondary endpoint: time to onset of T2D to Month 60, Additional endpoints: obesity-related complications, health-related quality of life, healthcare resource utilization, productivity, employment, sickness-related absences
- Study design/protocol
- 5-year
- Phase 4
- Multicenter
- Open-label
- Pragmatic
- 1:1 randomization
- Integrated electronic healthcare record data
- Key secondary endpoint: time to onset of T2D to Month 60
- Additional endpoints: obesity-related complications, health-related quality of life, healthcare resource utilization, productivity, employment, sickness-related absences
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
SURMOUNT ‐ REAL UK : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity. Obesity (Silver Spring). Published 15 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →